Mr. Rob Hill reports

EMERALD HEALTH THERAPEUTICS APPOINTS CHIEF EXECUTIVE OFFICER

Emerald Health Therapeutics Inc. has appointed Riaz Bandali as chief executive officer. Mr. Bandali has over 25 years of experience in life sciences, with expertise in global operations, strategy development, innovation cultivation, mergers and acquisitions, and investment management spanning contract clinical and research services, analytical instrumentation, lab services, and venture capital. Mr. Bandali most recently served as president, early phase clinical services, for Syneos Health, an international clinical research organization.

"Mr. Bandali has driven the vision, strategy, innovation and execution of growth plans in a number of life sciences enterprises. He has managed rapidly growing businesses and global teams of over 900 people to achieve significant sales growth and profitability -- and he has a meticulous focus on process and the bottom line," said Dr. Avtar Dhillon, executive chairman and president of Emerald. "Emerald has implemented unique infrastructure and strategic partnerships to form the foundation for its growth in the emerging global legal cannabis and cannabinoid market, and Riaz is very well equipped to lead our team to leverage and build on our competitive positioning with the goal of achieving growing, sustainable and profitable revenue streams."

Mr. Bandali previously served as president, early stage development, inVentiv Health Clinical; senior vice-president, strategy and business development, AB Sciex and Molecular Devices; vice-president and general manager, global early stage development, at MDS Pharma Services; and venture partner and vice-president, MDS Capital.

Mr. Bandali holds a master of business administration from McGill University, a bachelor of science from the University of British Columbia and has completed the advanced management program at the Harvard Business School.

Expansion of Emerald's C-suite

Emerald has also appointed Thierry Schmidt as its chief commercial officer. Mr. Schmidt will oversee all sales, marketing and product development for Emerald. He is a marketing, brand/product management, sales and business development expert who brings over 20 years of consumer goods experience, having worked at L'Oreal, Avon and British American Tobacco. Mr. Schmidt will maintain his current position as president of Verdelite, Emerald's cannabis cultivation, production and packaging facility in St. Eustache, Que.

"We have committed significant resources to the construction and launch of our Pure Sunfarms joint venture, which we believe is a leader among Canadian cannabis greenhouse operations. We have also substantially completed the buildout of other strategic operating assets and partnerships and are preparing to move them into commercialization ramp-up," said Dr. Dhillon. "As we advance our product innovation and development initiatives focused on differentiated, value-added products serving consumers seeking both recreational and wellness benefits, we are pleased to have Thierry's expertise and energy contributing to these important next steps of our growth plan."

Dr. Dhillon will continue in his role as executive chairman and president. Rob Hill and Sean Rathbone will continue in their respective roles as chief financial officer and chief operating officer.

The appointments of Mr. Bandali and Mr. Schmidt are subject to the customary approval of the TSX Venture Exchange.

About Emerald Health Therapeutics Inc.

Emerald Health Therapeutics is a Canadian licensed producer of cannabis products, with strategic initiatives focused on differentiated, value-added product development for medical and adult-use customers supported by novel intellectual property, large-scale cultivation, extraction and softgel encapsulation, as well as unique marketing and distribution channels.

We seek Safe Harbor.